Results 1 - 10 of 21 : 1 2 3 Next
Investor sentiment is getting behind these stocks that are set to run.
This drugmaker may be down, but it's not yet out.
You don't need a million to make millions. Just follow this simple four-step plan.
The End for (Another) Hepatitis C Drug Candidate
ViroPharma stops development of its compound after data showed it may hurt the liver.
You don't need million to make millions. Just follow this simple four-step plan.
Gilead gets a new approval for a drug.
More Than Momentum: Stocks Rising for a Reason
Sorting a bona fide growth story from a nine-day wonder.
Actions speak louder than words.
Are they cheap for a reason, or are they overlooked investment opportunities?
Hepatitis-treatment progress takes a step back in Q3.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK